Researchers and scientists from many countries recognize the effectiveness of Heberprot-P in the treatment to patients suffering from diabetic foot ulcer
December 12, 2016
VARADERO. Matanzas. - Today, Heberprot-P is registered in 23 countries from all the continents and is used effectively in ten countries, as reported in the 4th International Congress for the Control of Diabetes and its more severe complications.
The event held in the Plaza America Convention Center was attended by 600 delegates, with 250 from 38 countries.
Head of the Scar Formation group from the Center for Genetic Engineering and Biotechnology CIGB, Doctor in Sciences Jorge Berlanga, said the biggest award as a researcher is to have the product for the patients’ beds.
“We have Fidel’s legacy, who in 1989 announced that we had the epidermal growth factor, which was used for the treatment of burns, and spread in a sort of reorientation given the great biologic and pharmacologic potentials of the growth factor.”
“In the United States there is a high rate of diabetics, obesity, and pre-diabetics, who can be at a risk of suffering from diabetic foot ulcers. However, if Heberprot-P is introduced in that country the amputations will decrease significantly,” said the researcher.
A member of the American delegation Antonio C. Martínez considered that this medicine is going places and hopefully the regulatory clinical tests will end with the permission of the Treasury Department so that it can be introduced in the American market which would reduce the cost of the treatment of patients with diabetic foot ulcers.
CIGB Specialist Master in Sciences Giraldo Alonso Suárez assured that Heberprot-P has been applied to more than 60,000 Cuban patients, which has lowered the risk of amputation by 71%.
Alonso Suárez stressed that the goals of the congress were to promote academic-medical-scientific exchanges among first-level foreign specialists and Cubans; in addition to making the international publication of the results of Cuba’s health system in the battle against diabetes and cardiovascular diseases easier; and showing the achievements in the treatment of the diabetic foot ulcers with the application of Heberprot-P and other therapies.
Specialists in angiology, endocrinology, podiatry, surgeons, and nurses among others, debated in four symposiums about the topics related to scar formation in diabetes and its control, therapies for diabetic foot ulcers and health programs for diabetic patients.
Translated by ESTI